SF3B1 and acute myeloid leukemia: Similarly, the 2022 European Leukemia Net (ELN) recommendations incorporated mutations in BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2 into the adverse risk category of AML on top of their 2017’s recommendations to define cases with an MDS-like signature [64,65].